Researchers also demonstrated using a patient-derived organotypic tumor spheroids (PDOTS) and a matched PDO drug screening platform that inhibition of innate immune kinase TANK-binding kinase 1 coupled with PD-1 blockade was an effective strategy for overcoming tumor immunotherapy resistance (63). This evidence concerns the gene TBK1 and neoplasm.